Not finding it? Sign in to also search OpenAlex live.
-
Direct Observation of Solid-Phase Crystallization of an Amorphous Complex Oxide in the Transmission Electron Microscope2023 ECS Meeting Abstracts conference-abstract Materials Science Advancements in Solid Oxide Fuel Cells
Jenna L. Wardini, George Frederick Harrington, Dennis Kemp, Roger A. De Souza, William J. Bowman
0citations -
Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response
Susanne Isfort, Dominik Georg Friedrich Wolf, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +11 more
5citations -
Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).2023 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
George K.K. Lau, Bruno Sangro, Oxana Crysler, Wattana Sukeepaisarnjaroen, Oleg Nikolaevich Lipatov, Manabu Morimoto, +12 more
8citations -
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Hartmut Goldschmidt, Eva Nievergall, Roland R. Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, +25 more
33citations -
Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
Morag Griffin, Richard J. Kelly, Mathilde Gavillet, Petra Muus, Britta Hoechsmann, W. Jason Cummings, +4 more
4citations -
Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Michael Alan Rosenzweig, Yvonne Adeduni Efebera, Efstathios Kastritis, Brandon Jamaal Blue, Faizi A. Jamal, Monique C. Minnema, +10 more
1citations -
First safety analysis of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluoruracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).2025 Journal of Clinical Oncology conference-abstract Medicine Pancreatic and Hepatic Oncology Research Open access
Dirk Waldschmidt, Nam Gyu Im, Alexander Ioannis Damanakis, Thomas Schmidt, Albrecht Meyer zu Schwabedissen, Alexander Quaas, +13 more
0citations -
Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status
Heiko Becker, Claudia Schmoor, Olga Grishina, Dietmar Pfeifer, Dennis Zimmer, Martina Margrit Crysandt, +27 more
3citations -
Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study2020 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Kenshi Suzuki, Ashutosh D. Wechalekar, Kihyun Kım, Chihiro Shimazaki, Jin Seok Kim, Takayuki Ikezoe, +15 more
2citations -
Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial
Andreas Hochhaus, Andreas Burchert, Susanne Saußele, Gabriela Maria Baerlocher, Jiřı́ Mayer, Tim H. Brümmendorf, +21 more
21citations -
Treatment of multiple traumatized adolescents by enhancing regulation skills and reducing trauma related symptoms: rationale, study design, and methods of randomized controlled trial (the Mars-study)2023 BMC Psychiatry conference-abstract Psychology Posttraumatic Stress Disorder Research Open access
Rik Knipschild, Helen Klip, Doenja Leeuwaarden, Mariken J. R. van Onna, Ramón Lindauer, Wouter Staal, +1 more
8citations -
POS0409 HEALTHCARE STRUCTURES FOR RARE (METABOLIC) DISEASES IN GERMANY – HEALTHCARE RESEARCH USING STATUTORY HEALTH INSURANCE (SHI) DATA [SCOPE-RD: STUDY OF COVID-19 OUTCOMES IN PATIENTS WITH RARE DISEASES]2025 Annals of the Rheumatic Diseases conference-abstract Medicine COVID-19 and healthcare impacts Open access
Lukas Völkel, Lucas R.D. Fahrenschon, Martin Mücke, Benno Neukirch, Annette Doris Wagner
0citations -
EP1067 - ECE_2795 - Changes in cognitive and psychological functioning in patients with prolactinoma after treatment2026 European Journal of Endocrinology conference-abstract Medicine Pituitary Gland Disorders and Treatments Open access
Iris C. M. Pelsma, Willem Verbeek, Victoria River van Trigt, Leontine E. H. Bakker, Cornelie D. Andela, Nienke Ruurdje Biermasz
0citations -
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.2023 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
Kristoffer Staal Rohrberg, Mariana Brandão, Eduardo Castañón Álvarez, Enriqueta Felip, Eelke Hiddo Gort, T. Jeroen N. Hiltermann, +14 more
22citations -
Apply-PNH: Analysis of complement pathway biomarkers provides evidence for pharmacodynamic response in PNH patients who receive oral iptacopan monotherapy versus continuing anti-C5 therapy2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Richard Kelly, Austin Gladston Kulasekararaj, Alexander Röth, Phillip Scheinberg, Yasutaka Ueda, +4 more
0citations -
Potassium Supplementation Decreases Plasma Fibroblast Growth Factor 23 and Increases Plasma Phosphate in Stage 3b-4 CKD Patients: Single-Arm Intervention Study2021 Journal of the American Society of Nephrology conference-abstract Medicine Parathyroid Disorders and Treatments
Stanley M.H. Yeung, Martin Gritter, Rosa D. Wouda, Stephan J. L. Bakker, Jelmer J. van Zanden, Joris I. Rotmans, +3 more
0citations
23 results